Myriad Genetics, Inc.

Myriad Announces Prolaris(R) Test Biopsy Results From EMPATHY-P Study at European Association of Urology Annual Meeting

Myriad Obtains CE Mark for Tumor BRACAnalysis CDx(TM) and Launches Test in Europe as Companion Diagnostic for PARP Inhibitors

Myriad Establishes Tumor BRACAnalysis CDx(TM) Laboratory in Europe

Crescendo Bioscience’s Vectra(R) DA Predicts Radiographic Progression in Patients With Early Rheumatoid Arthritis

Crescendo Bioscience’s Vectra(R) DA Predicts Radiographic Progression in Patients With Early Rheumatoid Arthritis

Myriad Genetics Submits Premarket Approval to FDA for BRACAnalysis(R)

Myriad Genetics Submits Premarket Approval to FDA for BRACAnalysis(R)

/K I L L K I L L K I L L — Myriad Genetics, Inc.

Myriad Genetics Submits Premarket Approval to FDA for BRACAnalysis(R)

Myriad Genetics Submits Premarket Approval to FDA for BRACAnalysis(R)

Institut Pasteur and Myriad RBM Publish Initial Results From Landmark Study of Immune Response

Institut Pasteur and Myriad RBM Publish Initial Results From Landmark Study of Immune Response

Myriad Genetics and Sividon Diagnostics Announce Exclusive Co-Marketing Agreement for EndoPredict(R) Outside of the United States

Myriad Genetics and Sividon Diagnostics Announce Exclusive Co-Marketing Agreement for EndoPredict(R) Outside of the United States